Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab effects on skin barrier function in moderate to severe atopic dermatitis
2020-000314-15Phase 4
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoint: Percent change in transepidermal water loss after 5 skin tape strippings on lesional skin.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-000314-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000314-15.